

2026

Network for Cardiovascular Pharmacogenomics and Precision Medicine



CA24165



Building a European Network for
Cardiovascular Pharmacogenomics and
Precision Medicine!

Content editors: SCC Theodora Katsila
and Deputy SCC Amra Džuho

Contact: info@cardiopharmagenet.eu

Duration: 29.10.2025. - 28.10.2029.

The first newsletter of the CardioPharmaGENET
highlights the key milestones, collaborations and
achievements of our network during its inaugural year.

As we continue to build a strong European community
dedicated to advancing cardiovascular
pharmacogenomics and precision medicine, this
newsletter reflects the collective efforts of our
members in research, training, networking, and
scientific dissemination.



This newsletter is based upon work from COST Action CA24165 CardioPharmaGENET, supported by COST (European Cooperation in Science and Technology). COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.



About the CardioPharmaGENET

59 MC MEMBERS

FROM 37 COUNTRIES

301 ACTION PARTICIPANTS

FROM 42 COUNTRIES

4 YEARS

29/10/2025 – 28/10/2029

Data from 1st September, 2026

CardioPharmaGENET is a pan-European scientific network dedicated to advancing cardiovascular pharmacogenomics and precision medicine.

By bringing together researchers, clinicians, geneticists, pharmacologists, bioinformaticians, policymakers, industry representatives, and patient stakeholders, the Action promotes interdisciplinary collaboration to accelerate the translation of pharmacogenomic evidence into routine cardiovascular care.

Through knowledge sharing, capacity building, and the development of evidence-based recommendations, CardioPharmaGENET aims to support safer, more effective, and more personalised cardiovascular therapies across Europe.

Aim of the Action

The primary aim of CardioPharmaGENET is to facilitate the implementation of pharmacogenomics in cardiovascular medicine by consolidating scientific evidence, strengthening collaboration across disciplines, and supporting the development of harmonised clinical and policy recommendations.

The Action seeks to bridge the gap between research and clinical practice, promote the responsible use of artificial intelligence and large-scale genomic data, enhance education and training opportunities, and foster a sustainable European network that advances personalised cardiovascular medicine while improving patient outcomes and reducing healthcare inequalities.



Meet our working groups

1

Current Landscape and Status of PGx in Cardiovascular Medicine

WG1 focuses on assessing the current state of pharmacogenomics (PGx) implementation in cardiovascular medicine across Europe.

The group maps existing research infrastructure, evaluates clinical adoption of PGx-guided therapies, identifies technological and regulatory gaps, and develops evidence-based recommendations to support the wider integration of precision medicine into cardiovascular healthcare.

Dr. Miron Sopić
University of Belgrade – Faculty
of Pharmacy
miron.sopic@pharmacy.bg.ac.rs

2

Pharmacogenetic Guideline Development and Optimization

WG2 focuses on developing and optimizing PGx guidelines to support personalized cardiovascular therapies. The group systematically evaluates cardiovascular conditions, pharmacogenomic biomarkers, actionable genetic variants, and existing clinical guidelines to identify opportunities for improving treatment efficacy, safety, and clinical implementation.

Through evidence-based analyses and interdisciplinary collaboration, WG2 develops recommendations that facilitate the integration of pharmacogenomics into routine cardiovascular care.

Dr. Amela Jusić
Quant Biomarkers
amelajusic88@gmail.com

3

AI/ML Use in PGx of Cardiovascular Medicine

WG3 focuses on the development and application of artificial intelligence (AI)-assisted clinical decision support systems to facilitate the implementation of pharmacogenomics in cardiovascular medicine.

By integrating genomic, clinical, pharmacological, and demographic data, the group aims to develop innovative AI-driven tools that support evidence-based therapeutic decisions and enable more precise, personalised treatment strategies for cardiovascular patients.

Dr. Lemana Spahić
Bosnia and Herzegovina Medical
and Biological Engineering
Society
lemana@verlabinstitute.com

Meet our working groups

4

Policy Regulation and Impact Analysis Across Europe

Prof. Damir Marjanović
**Institute for Anthropological
Research**
damir.marjanovic@inantro.hr

WG4 focuses on identifying and addressing regulatory, ethical, legal, and policy challenges associated with implementing pharmacogenomics in cardiovascular medicine.

The group works to harmonise regulatory approaches across Europe, support the development of evidence-based policy recommendations, and facilitate the integration of pharmacogenomics into healthcare systems through collaboration with regulatory authorities, policymakers, healthcare professionals, and other stakeholders.

Communication, Dissemination and Exploitation

5

WG5 is responsible for increasing the visibility, outreach, and long-term impact of the CardioPharmaGENET through strategic communication and dissemination activities.

The group promotes the exchange of knowledge among researchers, clinicians, healthcare professionals, policymakers, industry representatives, patient organisations, and the general public, ensuring that the Action's scientific outputs reach all relevant stakeholders and contribute to the implementation of cardiovascular pharmacogenomics across Europe.

Dr. Theodora Katsila
**National Hellenic Research
Foundation**
thkatsila@eie.gr

While each Working Group has a distinct mission, their activities are closely interconnected. Together, they create a collaborative framework that integrates scientific evidence, clinical implementation, artificial intelligence, regulatory perspectives, education, and stakeholder engagement. **Through this multidisciplinary approach, CardioPharmaGENET is building a strong European network that accelerates the adoption of pharmacogenomics in cardiovascular medicine and contributes to more personalised, effective, and equitable patient care.**

LECTURE ON PRECISION MEDICINE AT FOKUS PATIENT FUTURE DAYS

Dr. Yvan Devaux, Vice Chair of the CardioPharmaGENET COST Action, delivered a lecture on precision medicine within the brain–heart axis at the FOKUS Patient Future Days in Stockholm. The presentation also showcased the Action’s objectives and research priorities, highlighting its commitment to interdisciplinary collaboration, translational research, and international knowledge exchange.



FIRST ANNUAL MEETING BRINGS THE CARDIOPHARMAGENET COMMUNITY TOGETHER

The first Annual Meeting of the Action was held from 11–13 May 2026 at GSI Helmholtzzentrum für Schwerionenforschung in Darmstadt, Germany, bringing together researchers, clinicians, industry representatives, policymakers, patient stakeholders, and Young Researchers and Innovators from across Europe. The three-day programme included Management Committee and Core Group meetings, scientific sessions, Working Group discussions, and stakeholder engagement activities, covering pharmacogenomics in cardiovascular medicine, artificial intelligence, clinical translation, regulatory challenges, health economics, and science communication. Working Groups coordinated future deliverables and planned upcoming research, training, and dissemination activities. The meeting also highlighted the importance of cross-sector collaboration in advancing precision cardiovascular medicine and included a visit to the FAIR and GSI research facilities.





AT THE COST COMMUNICATION WORKSHOP IN BRUSSELS

In March 2026, CardioPharmaGENET participated in the COST Communication Workshop in Brussels, represented by Science Communication Coordinator (SCC) Dr. Theodora Katsila. The event provided valuable insights into current trends and best practices in science communication, highlighting the importance of effective dissemination, stakeholder engagement, and strategic communication within European research networks.


Participation in the workshop reinforced the Action's commitment to strengthening its communication activities and supporting the visibility and impact of cardiovascular pharmacogenomics research across Europe, with Working Group 5 playing a central role in these efforts.



STRENGTHENING RESEARCH-POLICY COLLABORATION

CardioPharmaGENET continues to promote stronger links between scientific research and evidence-based policymaking through active engagement with European institutions. During a meeting in Brussels, Dr. Adna Ašić, Chair of the Action, and Dr. Jonathan Gomez-Raja, Management Committee representative for Spain and Policy Adviser at the European Commission Joint Research Centre (JRC), discussed the role of pharmacogenomics in supporting future healthcare strategies and precision medicine policies.

The meeting highlighted the importance of translating scientific evidence into policy and reinforced CardioPharmaGENET's commitment to fostering collaboration between researchers, clinicians, and policymakers to accelerate the implementation of personalised cardiovascular medicine across Europe.



CARDIOPHARMAGENET PRESENTED AT THE ISABS & MAYO CLINIC CONFERENCE

CardioPharmaGENET was showcased at the 14th ISABS & Mayo Clinic Conference: Advances in Application of Artificial Intelligence in Precision Medicine in Dubrovnik, Croatia. During the conference, Dr. Adna Ašić, Chair of the Action, presented the network's vision, objectives, and multidisciplinary approach to advancing precision cardiovascular medicine through pharmacogenomics and integrated risk assessment.

The event provided an excellent platform to increase the visibility of the Action, engage with experts in precision medicine and artificial intelligence, and establish new collaborations that will support future research and innovation in cardiovascular pharmacogenomics.



STRENGTHENING SCIENCE, POLICY, AND INTERNATIONAL COLLABORATION

Amra Džuho, WG5 Vice Leader and Deputy Science Communication Coordinator of CardioPharmaGENET, participated in the COST Academy workshops Science for Policy and International Scientific Networking in Brussels, Belgium. The workshops focused on strengthening the links between scientific evidence, policymaking, stakeholder engagement, and international research collaboration.

Participation in these activities enhanced the Action's capacity in science communication, policy impact, and global networking, supporting CardioPharmaGENET's mission to promote multidisciplinary collaboration and accelerate the implementation of precision cardiovascular medicine across Europe.



CARDIOPHARMAGENET PRESENTED AT THE HELLENIC SOCIETY OF BASIC AND CLINICAL PHARMACOLOGY CONGRESS

CardioPharmaGENET was presented at the 13th Panhellenic Congress of the Hellenic Society of Basic and Clinical Pharmacology, held in Patras, Greece, where Eugenia Yiannakopoulou introduced the Action's vision, objectives, and ongoing activities. The presentation highlighted the network's multidisciplinary approach and opportunities for collaboration within the field of cardiovascular pharmacogenomics.

The congress provided an excellent platform to strengthen the visibility of CardioPharmaGENET, foster collaboration with the Hellenic Society of Basic and Clinical Pharmacology, and promote networking opportunities for researchers, including postdoctoral and early-career scientists.



PARTICIPATION IN COST ACADEMY TRAINING ON EU DECISION-MAKING

Dr. Adna Ašić, Chair of the CardioPharmaGENET COST Action, participated in the COST Academy training Understanding EU Decision-Making Processes: How to Advocate Your Interest. The programme provided practical insights into EU policymaking and strategies for effectively communicating scientific evidence to support evidence-based policy development.

The training strengthened the Action's capacity to engage with policymakers and promote the societal impact of cardiovascular pharmacogenomics research, reinforcing CardioPharmaGENET's commitment to translating scientific knowledge into informed healthcare policies and practice.



COST-EFFECTIVENESS OF PHARMACOGENOMICS-GUIDED TREATMENT IN CARDIOVASCULAR DISEASE

WG2 of CardioPharmaGENET (CA24165) contributed to an umbrella review examining the cost-effectiveness of pharmacogenomics-guided treatment in cardiovascular disease.

The work highlights that the key challenge for cardiovascular pharmacogenomics is increasingly not technological feasibility, but the translation of genetic information into clinically actionable treatment decisions. Effective implementation requires integration of pharmacogenomic results with clinical guidelines, prescribing systems, decision-support tools, and multidisciplinary care.

The findings further emphasise the importance of collaboration among clinicians, geneticists, pharmacologists, laboratories, healthcare systems, payers, and policymakers to support the responsible integration of pharmacogenomics into cardiovascular care.

Follow CardioPharmaGENET and be part of the network shaping the future of personalised cardiovascular medicine.



[ABOUT](#) [ACTION STRUCTURE](#) [NEWS](#) [DELIVERABLES](#) [CONTACT](#) [Instagram](#) [LinkedIn](#)

Network for Cardiovascular Pharmacogenomics and Precision Medicine

CardioPharmaGENET aims to advance personalized medicine in cardiovascular care by leveraging pharmacogenomics (PGx) to optimize drug therapies. In cardiovascular medicine, this approach is especially critical, given the significant patient variability in drug responses to therapies.

Stay up to date with the latest news, opportunities, and activities within the CardioPharmaGENET COST Action by following our official website and social media channels. Through these platforms, you can receive timely updates on upcoming calls, networking opportunities, scientific events, and activities available for members of our growing community.

In the coming period, CardioPharmaGENET will announce new opportunities, including Short-Term Scientific Missions (STSMs), Dissemination Grants, Conference Grants, and Virtual Mobility Grants, providing valuable support for collaboration, knowledge exchange, and professional development. Looking ahead to the second year of the Action, we are also excited to launch our first CardioPharmaGENET Summer School, offering a dedicated opportunity for training, learning, and interdisciplinary exchange in the field of cardiovascular pharmacogenomics and precision medicine.

